- Home
- ONDS vs BLRX Comparison
ONDS vs BLRX Comparison
Compare ONDS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONDS
- BLRX
- Stock Information
- Founded
- ONDS 2014
- BLRX 2003
- Country
- ONDS United States
- BLRX Israel
- Employees
- ONDS N/A
- BLRX N/A
- Industry
- ONDS Telecommunications Equipment
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ONDS Telecommunications
- BLRX Health Care
- Exchange
- ONDS Nasdaq
- BLRX Nasdaq
- Market Cap
- ONDS 326.8M
- BLRX 15.3M
- IPO Year
- ONDS N/A
- BLRX 2011
- Fundamental
- Price
- ONDS $2.13
- BLRX $4.70
- Analyst Decision
- ONDS Strong Buy
- BLRX Strong Buy
- Analyst Count
- ONDS 2
- BLRX 2
- Target Price
- ONDS $3.25
- BLRX $19.00
- AVG Volume (30 Days)
- ONDS 21.0M
- BLRX 77.7K
- Earning Date
- ONDS 08-13-2025
- BLRX 08-14-2025
- Dividend Yield
- ONDS N/A
- BLRX N/A
- EPS Growth
- ONDS N/A
- BLRX N/A
- EPS
- ONDS N/A
- BLRX N/A
- Revenue
- ONDS $10,815,867.00
- BLRX $22,340,000.00
- Revenue This Year
- ONDS $243.35
- BLRX N/A
- Revenue Next Year
- ONDS $118.81
- BLRX N/A
- P/E Ratio
- ONDS N/A
- BLRX N/A
- Revenue Growth
- ONDS N/A
- BLRX 91.68
- 52 Week Low
- ONDS $0.54
- BLRX $2.30
- 52 Week High
- ONDS $3.40
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- ONDS 60.24
- BLRX 57.56
- Support Level
- ONDS $1.71
- BLRX $4.05
- Resistance Level
- ONDS $1.93
- BLRX $4.64
- Average True Range (ATR)
- ONDS 0.20
- BLRX 0.38
- MACD
- ONDS -0.02
- BLRX -0.01
- Stochastic Oscillator
- ONDS 51.08
- BLRX 86.17
About ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.